CAS NO: | 2319647-76-0 |
规格: | ≥98% |
包装 | 价格(元) |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 400.92 |
---|---|
Formula | C21H20N2O2S.HCl |
CAS No. | 1338540-63-8 (free base); 1338541-25-5 (s-isomer); 1338545-92-8 (S-isomer HCl); 1338544-87-8 (HBr) |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 80 mg/mL (199.54 mM) |
Water: 80 mg/mL (199.54 mM) | |
Ethanol: 5 mg/mL (12.47 mM) | |
SMILES Code | O=C1NC2=C(C(C3=CC=C([C@@H](C)CN)C=C3)=C(O)C=C2C)C4=C1SC=C4.[H]Cl |
Synonyms | OTS-514; OTS 514; OTS514; OTS-514 HCl, OTS 514 Hydrochloride. |
In Vitro | In vitro activity: OTS514 strongly suppressed the growth of TOPK-positive cancer cells. It also shows significant growth-inhibitory effect on ovarian cancer cell lines with IC50 values of 3.0 to 46 nM. OTS514 has growth inhibitory effect on five kidney cancer cell lines, VMRC-RCW, Caki-1, Caki-2, 769-P and 786-O, in which TOPK was highly expressed. The IC50 values range from 19.9 to 44.1 nM Kinase Assay: OTS514 is a novel and highly potent inhibitor of the TOPK (T-LAK cell-originated protein kinase) with an IC50 value of 2.6 nM. Cell Assay: Cells were cultured in RPMI supplemented with 20% fetal bovine serum and 1×StemSpan CC100. Cells were treated with OTS514 (20 or 40 nM) or OTS964 (100 or 200 nM) for 48 hours. Collected cells were washed with PBS and resuspended in 100 ml of PBS followed by staining with CD41a antibody for 20 min at room temperature. Finally, the cells were washed with PBS again and then analyzed for CD41a staining by flow cytometry. Expression of STAT5 was examined by Western blot with an anti-STAT5 antibody. |
---|---|
In Vivo | Mouse xenograft studies with human lung cancer cells demonstrated the in vivo efficacy of OTS514 but found that the compound also caused severe hematopoietic toxicity [reduction of red blood cells (RBCs) and white blood cells (WBCs) associated with marked increase in platelets. Oral administration of OTS514 significantly elongated overall survival in the ES-2 abdominal dissemination xenograft model, compared with vehicle control (P < 0.001). |
Animal model | BALB/cSLC-nu/nu mice |
Formulation & Dosage | 5% glucose(for IV); 0.5% methylcellulose(by oral gavage);1, 2.5, and 5 mg/kg;IV or oral gavage |
References | Clin Cancer Res. 2016 Dec 15;22(24):6110-6117. Epub 2016 Jun 22; Oncotarget. 2016 Apr 5;7(14):17652-64; Sci Transl Med. 2014 Oct 22;6(259):259ra145 |